PTSD Treatment Isn't Working: What Are Your Options?

The direct answer first. This guide describes treatment for adults; children and adolescents follow a different pathway (NICE recommends psychological therapy sequences specific to young people and advises against drug treatment for PTSD in under-18s). If you are an adult with PTSD and the standard treatments have not helped (a proper course of trauma-focused therapy, an SSRI at adequate dose and duration, or both), you are not out of options, but the map of what remains is smaller and more honest than the headlines suggest. There is no approved psychedelic treatment for PTSD anywhere in the European Union. What exists is a defined set of routes: guideline psychotherapies with genuine evidence behind them, licensed medicines, off-label uses with mixed evidence, and a small number of real clinical trials. This guide walks through all of them, with what the evidence and the European guidelines actually say, and without pretending any door is more open than it is.

One reassurance before the list. Some people need more than one treatment approach, and both reference guidelines this page leans on: the UK's NICE guideline NG116 and Germany's S3-Leitlinie for post-traumatic stress disorder, plan explicitly for that case: a different trauma-focused therapy, a different format, medication added or switched. Two distinctions worth holding onto: improvement (response) is not the same as full recovery (remission), so "better but not well" is a common and legitimate place to be; and symptoms that persist after appropriate, well-delivered treatment do not mean you or your therapist did anything wrong. Nothing on this page is a recommendation of one option over another; which step fits you is a decision for you and a clinician who knows your history.

What the options actually are

That fact box is the compressed version; here is each option in turn, with the detail.

Trauma-focused psychotherapy: the first line, and the first thing to re-examine. Both reference guidelines put individual trauma-focused psychological therapy first for adults: NICE instructs clinicians to offer adults with PTSD an individual trauma-focused CBT intervention (cognitive processing therapy, cognitive therapy for PTSD, narrative exposure therapy or prolonged exposure), and to offer EMDR (eye movement desensitisation and reprocessing) to adults with non-combat-related trauma presenting more than three months after the event, or to consider it between one and three months if the person prefers it (NICE NG116); this is a specific NICE recommendation rather than a general rule about combat trauma, and the US VA/DoD guideline recommends EMDR more broadly, including for combat-related PTSD. The German S3 guideline takes the same trauma-focused line (AWMF 155-001). If a course "didn't work", the useful question is what was delivered and against which protocol, not a raw session count: NICE describes typical courses of 8 to 12 sessions but explicitly allows longer courses for people with complex needs or multiple traumas, some validated therapies are deliberately short (Written Exposure Therapy uses five sessions), and time spent on stabilisation, safety and building trust is a legitimate part of treatment rather than proof that therapy failed. General supportive counselling, though, is not trauma-focused therapy. If a properly delivered course has not helped, there is no established consensus on the single best next step: another trauma-focused approach, a different therapist, or a different delivery format are individualised options a clinician may offer after reassessing you, not a fixed rescue sequence. If you have genuinely completed a proper course and remain unwell, say exactly that to the next clinician: it changes what they offer you.

Medication: a real option in its own right. The guidelines position drug treatment for adults as a valid alternative, particularly when you prefer it to psychological therapy or when trauma-focused therapy is not available or not feasible: NICE names venlafaxine or an SSRI such as sertraline, reviewed regularly (NICE NG116). In the UK, where NICE's licensing note applies, two medicines, sertraline and paroxetine, are licensed for PTSD; venlafaxine's use is off-label, and licensing differs between countries, so check the position in yours. These medicines can help, but response varies between people and outcomes; no single "average effect" figure describes them all fairly. If a first SSRI has not helped, switching or adjusting dose and duration are ordinary next moves for the prescriber. Combining medication with trauma-focused therapy can be considered case by case, but an additional PTSD benefit from the combination over either treatment alone has not been established, and choosing medication does not mean you must also complete trauma work. Antipsychotic augmentation is not a routine next step: NICE reserves it for disabling symptoms that have not responded to other treatments, given alongside psychological therapy and with specialist review, and guidelines disagree here (the VA/DoD guideline advises against risperidone for PTSD); antipsychotics carry metabolic and movement-related risks and need ongoing monitoring.

Residual symptoms: sleep, nightmares, anger. If the loudest remaining problems are insomnia, nightmares or anger rather than the full syndrome, say so specifically: NICE supports symptom-focused cognitive behavioural interventions in selected circumstances, and treating a residual symptom is a different goal from treating PTSD overall. If medicines are discussed for these symptoms, keep that distinction in view. Benzodiazepines are not recommended as a treatment for PTSD; if you are already taking one, do not stop abruptly, and plan any change with your prescriber.

MDMA-assisted therapy: strong placebo-controlled data, and not an authorised medicine. Here is the story the headlines keep mangling, told straight. MDMA is an investigational entactogen. Two Phase 3 trials (MAPP1 in 2021, MAPP2 in 2023, both in Nature Medicine) found MDMA plus the study's psychotherapy superior to placebo plus the same psychotherapy; they did not compare MDMA-assisted therapy against trauma-focused CBT, EMDR or antidepressants, so they establish nothing about superiority over existing treatments. And it is not an authorised PTSD medicine in the EU or the US: in August 2024 the US FDA declined approval, issuing a Complete Response Letter whose concerns included incomplete adverse-event and abuse-potential reporting, selection and expectancy bias on top of participants generally knowing their treatment allocation, and insufficient evidence of durability; it recommended a new trial with longer follow-up and fuller safety assessment. Since then the picture has moved: in August 2026 Resilient Pharmaceuticals, the successor to MAPS PBC/Lykos Therapeutics, resubmitted the NDA to the FDA, explicitly without a new Phase 3 trial, citing the FDA's July 2026 guidance on psychedelic drug development; a decision is pending (Psychedelic Alpha, August 2026). The FDA's decision governs the US only; the EU decides separately. On the EU side, the latest published EMA list of medicines under evaluation does not include midomafetamine (MDMA); that list covers validated applications whose evaluation has begun, so it cannot rule out a submission awaiting validation or a later filing, and no one can honestly predict approval timing. Lack of a marketing authorisation is not the whole legal picture, though: national controlled-drug permissions, research approvals and exceptional-access routes are separate questions that differ by country. The verified supervised routes today are clinical trials and narrow national programmes such as Switzerland's (next paragraph); if a provider claims any other authorisation, verify that specific claim with the national medicines or narcotics regulator before engaging. The full evidence review, including the trial results and the FDA's reasons, is in our MDMA evidence review.

Switzerland's exceptional-access programme is not a travel route. Under Switzerland's limited-medical-use provision, the federal health office BAG can grant patient-specific exceptional licences for MDMA-assisted treatment, but the conditions are strict: the patient must be resident in Switzerland, the applying physician must be authorised to practise there, the application needs the patient's written consent and an individual justification, and equivalent authorised alternatives must have been exhausted first. It is not a programme a reader elsewhere in Europe can travel into.

Ketamine and esketamine: related medicines, mixed evidence for PTSD. Ketamine is a licensed anaesthetic used off-label for depression in private clinics, and esketamine nasal spray (Spravato) is EU-approved for specific depression indications, not PTSD (EMA EPAR). For PTSD itself the ketamine evidence is genuinely mixed, not just early: a positive 30-person trial (Feder et al., 2021) was followed by a 158-person trial in military personnel and veterans that found no significant PTSD advantage over placebo, despite an antidepressant effect (Abdallah et al., 2022), and the VA/DoD guideline suggests against ketamine for PTSD. Those findings concern racemic ketamine and do not transfer to intranasal esketamine, which has not been shown effective for PTSD either. Esketamine's actual EU indication is precise: adults with a current moderate-to-severe major depressive episode who have not responded to at least two antidepressant treatments, taken in combination with an SSRI or SNRI; there is also a separate indication for rapid reduction of depressive symptoms in a psychiatric emergency, alongside oral antidepressant therapy. Neither is a PTSD indication, and low mood plus two past prescriptions does not by itself establish eligibility or funding; that assessment belongs to a psychiatrist. Safety deserves a plain paragraph of its own: ketamine and esketamine can cause dissociation, sedation and blood-pressure increases, and carry misuse potential, so proper assessment and clinical monitoring are required; with Spravato, you are observed at the clinic until clinically stable, and you should not drive until the next day after a restful sleep. And one honest caveat ties it together: successfully treating the depression that travels with PTSD does not establish that these medicines treat the PTSD itself. The full evidence is in our esketamine evidence review and ketamine evidence review, and the depression-side options in depression treatment isn't working: your options.

Psilocybin and the rest: trials, plus one tightly controlled national framework. No classic psychedelic holds a marketing authorisation for PTSD anywhere, and the European PTSD trial pipeline is small; the current studies, with registry numbers, are in the trials section below. Marketing authorisation is not the only lawful basis, though: Czechia's national psilocybin framework, in force since 2026, includes a conditional category for serious, life-threatening deterioration of other disorders, requiring scientific justification and failure of standard care, and its guidance discusses PTSD (Czech Ministry of Health, controlled-substances framework). That is a narrow, clinician-initiated route, not routine PTSD eligibility, and it is not proof of efficacy for PTSD. Rather than treating every non-trial offer as automatically illegal, the practical rule is: ask any provider for the exact legal basis and indication under which they would treat you, and verify it with the national regulator. (And if the condition driving your search is different, this series has the same kind of map for depression, OCD and addiction.)

How to work out where you are

First: what have you actually tried? Write it down, in one document: every psychological therapy, with its type (was it trauma-focused?), the number of sessions, whether the trauma itself was worked on, and why it ended; every medicine, with name, highest dose, duration at that dose, effect and side effects; any hospitalisations or crisis episodes. Old letters, prescriptions and your GP record are the raw material. This is not busywork: "adequate course, adequately delivered" is what every assessor looks for, the psychiatrist deciding on a medication change, the therapist judging what to offer next, and the trial screener checking eligibility criteria. (If you are reading this for someone else, our guide for family members covers how to help without pushing.)

Second: where are you now? Symptom screeners are conversation material, not diagnoses, but they anchor an appointment. Our eligibility check runs validated screeners privately in your browser (including the PHQ-2 for the depression that so often travels with PTSD), and, once you add your country and treatment history, may identify options worth discussing with a clinician. It cannot establish a diagnosis, confirm that a route is safe or funded for you, or predict trial acceptance; those judgements need clinical assessment. For PTSD itself, a clinician may use an instrument such as the CAPS-5, one clinician-administered assessment interview among the tools in use; there is no self-test that replaces that.

Trials as an option

For MDMA and psilocybin, trials are the main legal route to supervised treatment in almost all of Europe, and the current pipeline is small. As of September 2026, the picture on the registries looks like this. A Dutch phase 2 pilot of high-intensity inpatient MDMA-assisted psychotherapy for treatment-refractory PTSD (HI-MAP) is underway at ARQ Centrum'45 in the Netherlands: an open-label, single-group study targeting 20 Dutch-speaking adults already receiving care there, with the registry listing enrolment by invitation only, a status that does not prove places remain (NCT06954025). Amsterdam UMC received authorisation in August 2026 for a 12-participant feasibility and safety study of MDMA-assisted therapy for adolescents with treatment-resistant PTSD; per CTIS, recruitment has not started, and this is research, not routine adolescent care (CTIS 2024-515184-65-01). A 12-person pilot of psilocybin-assisted psychotherapy for Dutch-speaking veterans of the Netherlands Armed Forces with PTSD is registered at ARQ but not yet recruiting (NCT07792538). An earlier completed European feasibility study of MDMA-assisted therapy ran across six sites in five countries; completion tells you the field is active, not that access exists now, and this small phase 2 study should not be confused with the phase 3 efficacy trials (NCT04030169). Registries change: check ClinicalTrials.gov and the EU's CTIS register directly, and read our trials guide for how phases, placebo and consent work. The ground rules: under EU rules, study medicines and protocol-required procedures are generally covered by the trial, subject to national law, though travel and other expenses may remain yours (EU Clinical Trials Regulation 536/2014, Article 92); screening criteria are strict; benefit is uncertain and, depending on the protocol, you may receive placebo; participation is voluntary and you can withdraw at any time without losing your usual care (NHS guidance for trial participants); and some protocols require supervised tapering of serotonergic antidepressants, a decision to weigh with your clinician, never alone.

Frequently asked questions

Is MDMA therapy available in Europe?

Mainly in clinical trials. MDMA has no EMA marketing authorisation and no national medicinal approval for PTSD in any EU country, so supervised MDMA treatment outside research is generally not available; the main exception is Switzerland's exceptional-access programme, which is limited to patients resident in Switzerland treated by physicians authorised to practise there, is usually self-paid and carries long waitlists. As of September 2026 the main European MDMA trial (ARQ Centrum'45, Netherlands) enrols by invitation. National rules on controlled drugs and exceptional access differ by country: if a provider claims a legal basis for offering MDMA, verify it with the national regulator before engaging.

Why isn't MDMA approved if the trials were positive?

Because positive trials and approval are not the same thing. The US FDA's August 2024 Complete Response Letter concluded the programme did not provide sufficiently reliable evidence: adverse-event and abuse-potential data collection was incomplete, durability was insufficiently shown, and selection and expectancy bias, on top of participants generally knowing whether they had received MDMA, could inflate the apparent effect. It recommended a new trial with longer follow-up and fuller safety assessment. In August 2026 the sponsor, now Resilient Pharmaceuticals, resubmitted the application without a new Phase 3 trial, citing the FDA's July 2026 psychedelics guidance; a decision is pending. That decision applies to the US; the EU decides separately, and the latest published EMA list of medicines under evaluation does not include midomafetamine, which covers validated applications under evaluation and cannot rule out a later filing.

Is ketamine or esketamine a treatment for PTSD?

Not an approved one, and the evidence is mixed. A small positive trial (Feder 2021, 30 participants) was followed by a larger military and veteran trial (Abdallah 2022, 158 participants) that found no significant PTSD advantage over placebo, and VA/DoD guidance suggests against ketamine for PTSD. Esketamine's EU authorisation covers defined depression indications: treatment-resistant depression after at least two failed antidepressants, taken with an SSRI or SNRI, plus a separate acute psychiatric-emergency indication. If you also have depression that meets those criteria, that route may be worth assessing for the depression, covered in our depression options guide; treating the depression does not treat the PTSD.

What actually works for PTSD, then?

For adults, trauma-focused psychotherapy, trauma-focused CBT or EMDR, has the strongest guideline backing and is the first-line treatment in the UK and German guidelines. In the UK, sertraline and paroxetine are the licensed medicines, and response varies from person to person. If a first course of either has not helped, the guidelines' answer is an individual reassessment and another evidence-based option delivered properly, not "nothing more can be done."

What if nothing has worked?

Say exactly that to a specialist, with your written treatment history in hand. Persistent symptoms after appropriate treatment are not a verdict on you, and non-response sometimes has findable reasons: a therapy that never reached the trauma work, comorbid depression, sleep disorder or substance use pulling the floor out, a diagnosis worth revisiting. The remaining moves are a specialist reassessment, further trauma-focused therapy chosen for your situation, medication changes, symptom-focused work on sleep, nightmares or anger, and trials. If the question behind the question is despair: do not wait for a booked appointment or trial screening if you may harm yourself or cannot stay safe; seek urgent help now. Call 112 or a crisis line; urgent assessment and treatment can help, and routine scheduling must not delay them.

Sources

1. NICE NG116: Post-traumatic stress disorder, recommendations
2. AWMF 155-001: S3-Leitlinie Posttraumatische Belastungsstörung (ADAPT)
3. VA/DoD Clinical Practice Guideline for the Management of PTSD
4. Mitchell JM et al. MDMA-assisted therapy for severe PTSD (MAPP1). Nature Medicine 2021
5. Mitchell JM et al. MDMA-assisted therapy for moderate to severe PTSD (MAPP2). Nature Medicine 2023
6. FDA Complete Response Letter, midomafetamine capsules NDA 215455 (August 2024, published by FDA)
7. EMA: Medicines for human use under evaluation (monthly CHMP list)
8. EMA: Spravato European Public Assessment Report and product information
9. Swiss Federal Office of Public Health (BAG): Exceptional licences for banned narcotics
10. Feder A et al. A randomized controlled trial of repeated ketamine administration for chronic PTSD. Am J Psychiatry 2021
11. Abdallah CG et al. Dose-related effects of ketamine for antidepressant-resistant symptoms of PTSD in veterans and active duty military. Neuropsychopharmacology 2022
12. Czech Ministry of Health: controlled substances and psilocybin framework
13. ClinicalTrials.gov NCT06954025: inpatient MDMA-assisted psychotherapy for treatment-refractory PTSD (HI-MAP, ARQ Centrum'45)
14. CTIS 2024-515184-65-01: MDMA-assisted therapy for adolescents with treatment-resistant PTSD (Amsterdam UMC)
15. ClinicalTrials.gov NCT07792538: psilocybin-assisted psychotherapy for veterans with PTSD (ARQ)
16. ClinicalTrials.gov NCT04030169: completed European phase 2 MDMA-assisted therapy study
17. Regulation (EU) No 536/2014 on clinical trials (Article 92, cost coverage)
18. NHS: Clinical trials, what taking part involves
19. Psychedelic Alpha: Two years after rejection, Resilient quietly refiles MDMA for PTSD application (August 2026)

---

This guide is for general information only and is not medical advice, a diagnosis, or a recommendation of any treatment. It does not describe doses, preparation or session experiences, and it is not a guide to obtaining any substance. Discuss your options with a licensed clinician who knows your history. If you are in crisis, contact your local emergency number (112 in the EU) or a crisis line immediately.